Healthy Aging News and ResearchREWIND trial: dulaglutide on cognitive impairment in T2D

User avatar
AlbertY
Posts: 144
Joined: Mon Aug 12, 2019 4:01 pm
Location: Boston, MA

REWIND trial: dulaglutide on cognitive impairment in T2D

Post by AlbertY » Mon Jun 29, 2020 9:15 pm

This human study shows that long-term treatment with dulaglutide might reduce cognitive impairment in people with type 2 diabetes.
This is the first treatment proven efficacy in attenuating cognitive decline in people with diabetes.
https://www.sciencedirect.com/science/a ... 2220301733


Ph.D. student at Harvard Medical School, doing research on aging
NewLifeScience
Posts: 240
Joined: Thu Aug 22, 2019 4:17 pm

Re: REWIND trial: dulaglutide on cognitive impairment in T2D

Post by NewLifeScience » Tue Jul 07, 2020 8:48 am

AlbertY wrote:
Mon Jun 29, 2020 9:15 pm
This human study shows that long-term treatment with dulaglutide might reduce cognitive impairment in people with type 2 diabetes.
This is the first treatment proven efficacy in attenuating cognitive decline in people with diabetes.
https://www.sciencedirect.com/science/a ... 2220301733
This is interesting for sure! Would it be safe for someone without Type 2 diabetes to take this?

Is it too soon to tell?
Taking:
Resveratrol 400mg since June 2019; 600mg since October 1; 800mg since January 2020
NMN Sublingual 250mg since june 2019 500mg since September 2019
NAD+ Nasal, appx 100mg per day since September 2019; 200mg per day beginning mid November
User avatar
AlbertY
Posts: 144
Joined: Mon Aug 12, 2019 4:01 pm
Location: Boston, MA

Re: REWIND trial: dulaglutide on cognitive impairment in T2D

Post by AlbertY » Tue Jul 07, 2020 2:12 pm

NewLifeScience wrote:
Tue Jul 07, 2020 8:48 am

This is interesting for sure! Would it be safe for someone without Type 2 diabetes to take this?

Is it too soon to tell?
Well, it hard to say, but note that T2D is a great risk factor for CVD and dementia. So it is possible that this drug only works in diabetic patients by reducing this risk through a specific pathway, but not in non-diabetic patients.

For T2D patients, definitely consider taking it under doctor's supervision.
Ph.D. student at Harvard Medical School, doing research on aging
Post Reply Previous topicNext topic